T. Macarulla Mercadé

Author

Also Known As

Ayala Hubert, D.A. Acosta Eyzaguirre, T Macarulla Mercade, T. M. Mercadé, T. Macarulla Mercade, T. Macarulla Mercadé, T.M. Mercade, Teresa M Mercadé, Teresa Macarulla Mercade, Teresa Macarulla Mercadé

123

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Vall d'Hebron Institute of Oncology Vall d'Hebron Hospital Universitari Samsung Medical Center Sungkyunkwan University Seoul National University Hospital

About

T. Macarulla Mercadé is an author at Vall d'Hebron Institute of Oncology specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	1.2K
2	Hepatology	4	4	143
3	Health Sciences	3	3	60
4	Biomedical Engineering	1	1	24
5	Genetic Medicine	1	1	20

T. Macarulla Mercadé

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Journal of Clinical Oncology	2022	120
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies Dejan Juric, Johann S. de Bono, Patricia LoRusso, Clinical Cancer Research	2017	89
ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation Ghassan K. Abou‐Alfa, T. Macarulla Mercadé, Milind Javle, Annals of Oncology Tumor BiologyIsocitrate Dehydrogenase 1OncologyHepatologyMedicine	2019	88
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020) Ma A. Gómez-España, Ana Fernández Montés, Rocio García‐Carbonero, Clinical & Translational Oncology	2021	46
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C Khaldoun Almhanna, David Wright, T. Macarulla Mercadé, Investigational New Drugs OncologyPancreatic CancerMedicineAntibody-drug ConjugatePathology	2017	34
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer T. Macarulla Mercadé, Li‐Tzong Chen, Chung‐Pin Li, Pancreas	2019	30
A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Davide Melisi, Antoine Hollebecque, Do‐Youn Oh, Journal of Clinical Oncology ImmunologyImmunoeditingImmunotherapeuticsImmunotherapyOncology	2019	28
Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study Eleni Gkika, Anca-Ligia Grosu, T. Macarulla Mercadé, Cancers Fields ConcomitantHepatologyGliomaAdvanced Hepatocellular CancerMedicine	2022	28
YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD) Antonio Cubillo Gracián, Andrew Dean, Andrés Muñoz, Annals of Oncology Arm Double-blindTruncated CoursesTherapeutic VaccineBiological TherapyBiomedical Engineering	2017	24

Page 1